My first dose of Semaglutide
US$ 20.78
glp 1 callout on packaging Food companies are targeting users of weight-loss drugs with 'GLP-1 Friendly' labels Weighty issue: GLP-1 drugs are
Description
NYT's opinion page: science can't keep pace with how people are actually using these drugs
Get exposed to over 2100 subscribers globally, most of whom are investors.
OEM/ODM scales, logos, and packaging for US, UK, and EU markets.
Background Identifying and reducing cardiometabolic risks driven by obesity remains a healthcare challenge
We're not friends anymore
Many doctors are still catching up with the science
